Christopher Gallagher
Overview
Explore the profile of Christopher Gallagher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
498
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schubel L, Rivera Rivera J, Pratt-Chapman M, Astorino J, Taylor T, Littlejohn R, et al.
J Psychosoc Oncol
. 2025 Feb;
:1-19.
PMID: 39946244
Objectives: This project aimed to understand the experiences and preferences for social risk factor screening among racially, ethnically, and linguistically diverse cancer survivors in the Washington, DC, region. Methods: Semi-structured...
2.
Fong A, Boxley C, Schubel L, Gallagher C, AuBuchon K, Arem H
JMIR Cancer
. 2025 Jan;
11:e57715.
PMID: 39828992
Background: Patients with cancer frequently encounter complex treatment pathways, often characterized by challenges with coordinating and scheduling appointments at various specialty services and locations. Identifying patients who might benefit from...
3.
Schubel L, Barac A, Magee M, Mete M, Peeples M, Shomali M, et al.
Contemp Clin Trials Commun
. 2025 Jan;
43():101387.
PMID: 39810843
Background: Black individuals with cancer have a higher prevalence of comorbidities and a worse cancer prognosis than other racial groups in the US. As part of a quality improvement project,...
4.
Schlam I, Smith D, Peer C, Sissung T, Schmidt K, Tan M, et al.
NPJ Breast Cancer
. 2024 Sep;
10(1):84.
PMID: 39349477
Underrepresented populations' participation in clinical trials remains limited, and the potential impact of genomic variants on drug metabolism remains elusive. This study aimed to assess the pharmacokinetics (PK) and pharmacogenomics...
5.
Swain S, Schlam I, Smith D, Peer C, Sissung T, Schmidt K, et al.
Res Sq
. 2024 Aug;
PMID: 39184092
Underrepresented populations' participation in clinical trials remains limited, and the potential impact of genomic variants on drug metabolism remains elusive. This study aimed to assess the pharmacokinetics (PK) and pharmacogenomics...
6.
Schubel L, Mete M, Fong A, Boxley C, Barac A, Gallagher C, et al.
J Ambul Care Manage
. 2024 Jul;
47(4):228-238.
PMID: 39028275
Navigating cancer care is complex and is exacerbated by pre-existing comorbidities managed by multiple providers. In this quality improvement study, we evaluated changes in perceived care coordination, navigation, and chronic...
7.
Lynce F, Mainor C, Donahue R, Geng X, Jones G, Schlam I, et al.
Nat Commun
. 2024 May;
15(1):3957.
PMID: 38730268
No abstract available.
8.
Lynce F, Mainor C, Donahue R, Geng X, Jones G, Schlam I, et al.
Nat Commun
. 2024 Mar;
15(1):2691.
PMID: 38538574
Chemotherapy and immune checkpoint inhibitors have a role in the post-neoadjuvant setting in patients with triple-negative breast cancer (TNBC). However, the effects of nivolumab, a checkpoint inhibitor, capecitabine, or the...
9.
Lynce F, Mainor C, Donahue R, Geng X, Jones G, Schlam I, et al.
medRxiv
. 2023 Dec;
PMID: 38105958
Chemotherapy and immune checkpoint inhibitors have a role in the post-neoadjuvant setting in patients with triple-negative breast cancer (TNBC). However, the effects of nivolumab, a checkpoint inhibitor, capecitabine, or the...
10.
Nicastro G, Abis G, Klein P, Esteban-Serna S, Gallagher C, Chaves-Arquero B, et al.
Nucleic Acids Res
. 2023 Jun;
51(16):8774-8786.
PMID: 37377445
m6A methylation provides an essential layer of regulation in organismal development, and is aberrant in a range of cancers and neuro-pathologies. The information encoded by m6A methylation is integrated into...